The MHRA has granted marketing authorisation for Eylea® (aflibercept 8 mg) for the treatment of patients with macular oedema following retinal vein occlusion (RVO) including branch, central and ...

Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched ...

In the United States, aflibercept-yszy received Food and Drug Administration (FDA) approval in May 2024 as a biosimilar to ...

More recently established treatments for RVO have taken a giant leap forward from laser photocoagulation since intravitreally ...

Ocular Therapeutix's current wet AMD treatment is dominated by anti-VEGF drugs, with EYLEA holding a 63% global market share in 2024. Read why OCUL stock is a sell.

Please provide your email address to receive an email when new articles are posted on . Eylea HD allowed for longer treatment intervals compared with Eylea and showed similar safety and efficacy.

Breye is advancing danegaptide to Phase II trials after the drug showed signs of improving disease activity in a Phase Ib ...

TARRYTOWN, N.Y., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced upcoming presentations from its ophthalmology portfolio and pipeline at the virtual ...

TARRYTOWN, N.Y., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced upcoming presentations from its ophthalmology portfolio and pipeline at the virtual ...

Plotting a challenge to Regeneron’s blockbuster Eylea, Ocular Therapeutix has hired “a key architect” of its rival’s launch to head its commercial team. David Robinson has joined Ocular as global ...

The most-read ophthalmology biosimilar stories of 2025 included FDA approvals and real-world data. The continued expansion of the biosimilar market into ophthalmology is helping to redefine treatment ...